- Home
- ANL vs MRSN Comparison
ANL vs MRSN Comparison
Compare ANL & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANL
- MRSN
- Stock Information
- Founded
- ANL 2004
- MRSN 2001
- Country
- ANL Cayman Islands
- MRSN United States
- Employees
- ANL N/A
- MRSN N/A
- Industry
- ANL
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- ANL
- MRSN Health Care
- Exchange
- ANL Nasdaq
- MRSN Nasdaq
- Market Cap
- ANL 79.0M
- MRSN 71.9M
- IPO Year
- ANL 2023
- MRSN 2017
- Fundamental
- Price
- ANL $2.25
- MRSN $0.53
- Analyst Decision
- ANL Strong Buy
- MRSN Buy
- Analyst Count
- ANL 2
- MRSN 7
- Target Price
- ANL $9.00
- MRSN $6.00
- AVG Volume (30 Days)
- ANL 5.8K
- MRSN 5.4M
- Earning Date
- ANL 03-04-2025
- MRSN 03-07-2025
- Dividend Yield
- ANL N/A
- MRSN N/A
- EPS Growth
- ANL N/A
- MRSN N/A
- EPS
- ANL N/A
- MRSN N/A
- Revenue
- ANL $5,000,000.00
- MRSN $34,837,000.00
- Revenue This Year
- ANL N/A
- MRSN N/A
- Revenue Next Year
- ANL N/A
- MRSN N/A
- P/E Ratio
- ANL N/A
- MRSN N/A
- Revenue Growth
- ANL N/A
- MRSN N/A
- 52 Week Low
- ANL $1.85
- MRSN $0.49
- 52 Week High
- ANL $17.48
- MRSN $6.28
- Technical
- Relative Strength Index (RSI)
- ANL 57.33
- MRSN 32.86
- Support Level
- ANL $2.00
- MRSN $0.56
- Resistance Level
- ANL $2.15
- MRSN $0.82
- Average True Range (ATR)
- ANL 0.11
- MRSN 0.07
- MACD
- ANL 0.03
- MRSN 0.03
- Stochastic Oscillator
- ANL 59.52
- MRSN 8.39
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.